Tuberculosis - United States, 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):265-270. doi: 10.15585/mmwr.mm7312a4.ABSTRACTAfter 27 years of declining U.S. tuberculosis (TB) case counts, the number of TB cases declined considerably in 2020, coinciding with the COVID-19 pandemic. For this analysis, TB case counts were obtained from the National TB Surveillance System. U.S. Census Bureau population estimates were used to calculate rates overall, by jurisdiction, birth origin, race and ethnicity, and age group. Since 2020, TB case counts and rates have increased each year. During 2023, a total of 9,615 TB cases were provisionally reported by the 50 U.S. sta...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Paula M Williams Robert H Pratt William L Walker Sandy F Price Rebekah J Stewart Pei-Jean I Feng Source Type: research
Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability - Sickle Cell Data Collection Program, 11 States, 2016-2020
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):248-254. doi: 10.15585/mmwr.mm7312a1.ABSTRACTSickle cell disease (SCD) remains a public health priority in the United States because of its association with complex health needs, reduced life expectancy, lifelong disabilities, and high cost of care. A cross-sectional analysis was conducted to calculate the crude and race-specific birth prevalence for SCD using state newborn screening program records during 2016-2020 from 11 Sickle Cell Data Collection program states. The percentage distribution of birth mother residence within Social Vulnerability Index quartiles was derived. A...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Mariam Kayle Audrey L Blewer Wei Pan Jennifer A Rothman Carri S Polick Joshua Rivenbark Elliott Fisher Camila Reyes John J Strouse Shelby Weeks Jay R Desai Angela B Snyder Mei Zhou Ankit Sutaria Jhaqueline Valle Sophia S Horiuchi Marci K Sontag Joshua I M Source Type: research
Ceftriaxone-Resistant Gonorrhea - China, 2022
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):255-259. doi: 10.15585/mmwr.mm7312a2.ABSTRACTGonorrhea is a widespread sexually transmitted infection; in 2022, China reported 96,313 cases of gonorrhea, making it the fourth most common notifiable infectious disease in the country after viral hepatitis, pulmonary tuberculosis, and syphilis. The rise in prevalence in antimicrobial-resistant strains, particularly the international spread of ceftriaxone-resistant clones, poses a formidable challenge to gonorrhea control. The China Gonococcal Resistance Surveillance Program (China-GRSP), established in 1987 and covering 19 of 34 p...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Xiaoyu Zhu Yue Xi Xiangdong Gong Shaochun Chen Source Type: research
Implications of Measles Inclusion by Commercial Syndromic Polymerase Chain Reaction Panels - United States, May 2022-April 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):260-264. doi: 10.15585/mmwr.mm7312a3.ABSTRACTSyndromic polymerase chain reaction (PCR) panels are used to test for pathogens that can cause rash illnesses, including measles. Rash illnesses have infectious and noninfectious causes, and approximately 5% of persons experience a rash 7-10 days after receipt of a measles, mumps, and rubella (MMR) vaccine. MMR vaccine includes live attenuated measles virus, which is detectable by PCR tests. No evidence exists of person-to-person transmission of measles vaccine virus, and illness does not typically result among immunocompetent person...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Christine M Thomas Amanda Hartley Ann Schmitz Heather D Reid Susan Sullivan Elise Huebner Meredith Robinson Adria Mathis Mary-Margaret A Fill Kara J Levinson Tim F Jones William Schaffner Caitlin N Newhouse John R Dunn Source Type: research
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):271-276. doi: 10.15585/mmwr.mm7312a5.ABSTRACTIn September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated ...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Ruth Link-Gelles Elizabeth A K Rowley Malini B DeSilva Kristin Dascomb Stephanie A Irving Nicola P Klein Shaun J Grannis Toan C Ong Zachary A Weber Katherine E Fleming-Dutra Charlene E McEvoy Omobosola Akinsete Daniel Bride Tamara Sheffield Allison L Nale Source Type: research
Tuberculosis - United States, 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):265-270. doi: 10.15585/mmwr.mm7312a4.ABSTRACTAfter 27 years of declining U.S. tuberculosis (TB) case counts, the number of TB cases declined considerably in 2020, coinciding with the COVID-19 pandemic. For this analysis, TB case counts were obtained from the National TB Surveillance System. U.S. Census Bureau population estimates were used to calculate rates overall, by jurisdiction, birth origin, race and ethnicity, and age group. Since 2020, TB case counts and rates have increased each year. During 2023, a total of 9,615 TB cases were provisionally reported by the 50 U.S. sta...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Paula M Williams Robert H Pratt William L Walker Sandy F Price Rebekah J Stewart Pei-Jean I Feng Source Type: research
Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability - Sickle Cell Data Collection Program, 11 States, 2016-2020
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):248-254. doi: 10.15585/mmwr.mm7312a1.ABSTRACTSickle cell disease (SCD) remains a public health priority in the United States because of its association with complex health needs, reduced life expectancy, lifelong disabilities, and high cost of care. A cross-sectional analysis was conducted to calculate the crude and race-specific birth prevalence for SCD using state newborn screening program records during 2016-2020 from 11 Sickle Cell Data Collection program states. The percentage distribution of birth mother residence within Social Vulnerability Index quartiles was derived. A...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Mariam Kayle Audrey L Blewer Wei Pan Jennifer A Rothman Carri S Polick Joshua Rivenbark Elliott Fisher Camila Reyes John J Strouse Shelby Weeks Jay R Desai Angela B Snyder Mei Zhou Ankit Sutaria Jhaqueline Valle Sophia S Horiuchi Marci K Sontag Joshua I M Source Type: research
Ceftriaxone-Resistant Gonorrhea - China, 2022
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):255-259. doi: 10.15585/mmwr.mm7312a2.ABSTRACTGonorrhea is a widespread sexually transmitted infection; in 2022, China reported 96,313 cases of gonorrhea, making it the fourth most common notifiable infectious disease in the country after viral hepatitis, pulmonary tuberculosis, and syphilis. The rise in prevalence in antimicrobial-resistant strains, particularly the international spread of ceftriaxone-resistant clones, poses a formidable challenge to gonorrhea control. The China Gonococcal Resistance Surveillance Program (China-GRSP), established in 1987 and covering 19 of 34 p...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Xiaoyu Zhu Yue Xi Xiangdong Gong Shaochun Chen Source Type: research
Implications of Measles Inclusion by Commercial Syndromic Polymerase Chain Reaction Panels - United States, May 2022-April 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):260-264. doi: 10.15585/mmwr.mm7312a3.ABSTRACTSyndromic polymerase chain reaction (PCR) panels are used to test for pathogens that can cause rash illnesses, including measles. Rash illnesses have infectious and noninfectious causes, and approximately 5% of persons experience a rash 7-10 days after receipt of a measles, mumps, and rubella (MMR) vaccine. MMR vaccine includes live attenuated measles virus, which is detectable by PCR tests. No evidence exists of person-to-person transmission of measles vaccine virus, and illness does not typically result among immunocompetent person...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Christine M Thomas Amanda Hartley Ann Schmitz Heather D Reid Susan Sullivan Elise Huebner Meredith Robinson Adria Mathis Mary-Margaret A Fill Kara J Levinson Tim F Jones William Schaffner Caitlin N Newhouse John R Dunn Source Type: research
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):271-276. doi: 10.15585/mmwr.mm7312a5.ABSTRACTIn September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated ...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Ruth Link-Gelles Elizabeth A K Rowley Malini B DeSilva Kristin Dascomb Stephanie A Irving Nicola P Klein Shaun J Grannis Toan C Ong Zachary A Weber Katherine E Fleming-Dutra Charlene E McEvoy Omobosola Akinsete Daniel Bride Tamara Sheffield Allison L Nale Source Type: research
Tuberculosis - United States, 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):265-270. doi: 10.15585/mmwr.mm7312a4.ABSTRACTAfter 27 years of declining U.S. tuberculosis (TB) case counts, the number of TB cases declined considerably in 2020, coinciding with the COVID-19 pandemic. For this analysis, TB case counts were obtained from the National TB Surveillance System. U.S. Census Bureau population estimates were used to calculate rates overall, by jurisdiction, birth origin, race and ethnicity, and age group. Since 2020, TB case counts and rates have increased each year. During 2023, a total of 9,615 TB cases were provisionally reported by the 50 U.S. sta...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Paula M Williams Robert H Pratt William L Walker Sandy F Price Rebekah J Stewart Pei-Jean I Feng Source Type: research
Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability - Sickle Cell Data Collection Program, 11 States, 2016-2020
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):248-254. doi: 10.15585/mmwr.mm7312a1.ABSTRACTSickle cell disease (SCD) remains a public health priority in the United States because of its association with complex health needs, reduced life expectancy, lifelong disabilities, and high cost of care. A cross-sectional analysis was conducted to calculate the crude and race-specific birth prevalence for SCD using state newborn screening program records during 2016-2020 from 11 Sickle Cell Data Collection program states. The percentage distribution of birth mother residence within Social Vulnerability Index quartiles was derived. A...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Mariam Kayle Audrey L Blewer Wei Pan Jennifer A Rothman Carri S Polick Joshua Rivenbark Elliott Fisher Camila Reyes John J Strouse Shelby Weeks Jay R Desai Angela B Snyder Mei Zhou Ankit Sutaria Jhaqueline Valle Sophia S Horiuchi Marci K Sontag Joshua I M Source Type: research
Ceftriaxone-Resistant Gonorrhea - China, 2022
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):255-259. doi: 10.15585/mmwr.mm7312a2.ABSTRACTGonorrhea is a widespread sexually transmitted infection; in 2022, China reported 96,313 cases of gonorrhea, making it the fourth most common notifiable infectious disease in the country after viral hepatitis, pulmonary tuberculosis, and syphilis. The rise in prevalence in antimicrobial-resistant strains, particularly the international spread of ceftriaxone-resistant clones, poses a formidable challenge to gonorrhea control. The China Gonococcal Resistance Surveillance Program (China-GRSP), established in 1987 and covering 19 of 34 p...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Xiaoyu Zhu Yue Xi Xiangdong Gong Shaochun Chen Source Type: research
Implications of Measles Inclusion by Commercial Syndromic Polymerase Chain Reaction Panels - United States, May 2022-April 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):260-264. doi: 10.15585/mmwr.mm7312a3.ABSTRACTSyndromic polymerase chain reaction (PCR) panels are used to test for pathogens that can cause rash illnesses, including measles. Rash illnesses have infectious and noninfectious causes, and approximately 5% of persons experience a rash 7-10 days after receipt of a measles, mumps, and rubella (MMR) vaccine. MMR vaccine includes live attenuated measles virus, which is detectable by PCR tests. No evidence exists of person-to-person transmission of measles vaccine virus, and illness does not typically result among immunocompetent person...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Christine M Thomas Amanda Hartley Ann Schmitz Heather D Reid Susan Sullivan Elise Huebner Meredith Robinson Adria Mathis Mary-Margaret A Fill Kara J Levinson Tim F Jones William Schaffner Caitlin N Newhouse John R Dunn Source Type: research
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024
MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):271-276. doi: 10.15585/mmwr.mm7312a5.ABSTRACTIn September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated ...
Source: MMWR Morb Mortal Wkl... - March 28, 2024 Category: Epidemiology Authors: Ruth Link-Gelles Elizabeth A K Rowley Malini B DeSilva Kristin Dascomb Stephanie A Irving Nicola P Klein Shaun J Grannis Toan C Ong Zachary A Weber Katherine E Fleming-Dutra Charlene E McEvoy Omobosola Akinsete Daniel Bride Tamara Sheffield Allison L Nale Source Type: research
